The 36-month PFS rate for patients with del (17p) and/or TP53 mutation was 87% and for patients without del (17p) and TP53 mutation was 89%. The safety profile of BRUKINSA plus venetoclax was ...
Dr Suchitra Sundaram reflects on time limited venetoclax combinations, next generation non covalent BTK inhibitors, and novel ...
Longitudinal data reveal consistent initial responsiveness to targeted agents but limited durability once patients cycle through both BTKi and BCL2i classes.
The CLL17 trial showed noninferiority of fixed-duration regimens compared to continuous BTK inhibitor therapy, highlighting ...
In a recently published study, researchers at Fox Chase Cancer Center revealed for the first time that cancer cells can evade anti-cancer drugs by entering and surviving within bone marrow fibroblasts ...
Here are the top 5 articles detailing the advancements in hematologic oncology from 2025. BTK inhibitors have revolutionized ...
Efficacy of first-line treatment for chronic lymphocytic leukemia: A Bayesian network meta-analysis.
Incidence, predictors and outcomes of cardiovascular events in patients with chronic lymphocytic leukemia. Summary of NMA results: PFS of zanubrutinib compared with frontline treatments for TN CLL.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback